WE CLAIM:

1. A compound of formula I



(I)

or a stereoisomer or pharmaceutically acceptable salt thereof,

wherein

X is –N- or –CH-;

R^1 is -C(O)R^{1a};

R^{1a} is C_{3-6} cycloalkyl;

R^2 is C_{1-6} alkoxy;

R^3 is C_{1-6} alkyl or C_{3-6} cycloalkyl.

2. The compound according to claim 1 of the formula



(I)

or a stereoisomer or pharmaceutically acceptable salt thereof,

wherein

R^1 is -C(O)R^{1a};

R^{1a} is C_{3-6} cycloalkyl;

R^2 is C_{1-6} alkoxy;

R^3 is C_{1-6} alkyl or C_{3-6} cycloalkyl.

3. The compound according to claim 1 of the formula



or a stereoisomer or pharmaceutically acceptable salt thereof,

wherein

R^1 is -C(O)R^{1a};

R^{1a} is C_{3-6} cycloalkyl;

R^2 is C_{1-6} alkoxy;

R^3 is C_{1-6} alkyl or C_{3-6} cycloalkyl.

4. A compound or a pharmaceutically acceptable salt thereof, selected from

N-(4-((3-methoxy-4-(2-methyl-2H-1,2,3-triazol-4-yl)pyridin-2-yl)amino)-5-propionylpyridin-2-yl)cyclopropanecarboxamide,

N-(4-((3-methoxy-4-(2-cyclopropyl-2H-1,2,3-triazol-4-yl)pyridin-2-yl)amino)-5-propionylpyridin-2-yl)cyclopropanecarboxamide,

N-(4-((2-methoxy-3-(2-methyl-2H-1,2,3-triazol-4-yl)phenyl)amino)-5-propionylpyridin-2-yl)cyclopropanecarboxamide,

N-(4-((4-fluoro-2-methoxy-3-(2-methyl-2H-1,2,3-triazol-4-yl)phenyl)amino)-5-propionylpyridin-2-yl)cyclopropanecarboxamide,

N-(4-((3-fluoro-2-methoxy-3-(2-methyl-2H-1,2,3-triazol-4-yl)phenyl)amino)-5-propionylpyridin-2-yl)cyclopropanecarboxamide, and

N-(4-((3-methyl-2-methoxy-3-(2-methyl-2H-1,2,3-triazol-4-yl)phenyl)amino)-5-propionylpyridin-2-yl)cyclopropanecarboxamide.

5. A pharmaceutical composition comprising one or more compounds according to claim 1 and a pharmaceutically acceptable carrier or diluent.

6. A pharmaceutical composition comprising one or more compounds according to claim 4 and a pharmaceutically acceptable carrier or diluent.

7. Use of the compound according to claim 1 in the manufacture of a medicament for treating a neurodegenerative disease, wherein a therapeutically-effective amount of the compound is to be administered to a patient in need of such treatment.

8. The use of claim 7, wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, ALS, Multiple Sclerosis (RMS and/or progressive MS, including CIS, optic neuritis, neuromyelitis optica).

9. The compound according to claim 1 for use in therapy.